Publications


YAM Laboratory

#First author; *Corresponding author

2021

  • Leung L, Lau N, Liu J, Qu X, Tsui SKW, Hou J, Law CTY, Ng TH, Yam JWP, Chow C, Chan ABW, Chan JYK, Meehan K*. The role of arginine metabolism in oral tongue squamous cell carcinoma. (Submitted)
  • Wang SQ, Chen JJ, Yam JWP, Wong MP, Xiao ZJ*. Lung adenocarcinoma resilience and stem cell phenotypes are enhanced through CaMK2A/NRF2/GSTP1 axis. (Submitted)
  • He R, Wang Z, Shi W, Yu L, Meng N, Wang H, Xia H, Huang Z, Liu S, Zhao X, Xu Y*, Yam JWP*, Cui Y*. Long non-coding RNAs in hepatocellular carcinoma: novel regulators of drug resistance. (Submitted)
  • Tey SK, Lam H, Wong SWK, Zhao H, To KKW*, Yam JWP*. ACE2-enriched extracellular vesicles enhance infectivity of live SARS-CoV-2 virus in an endocytosis-dependent manner. Journal of Extracellular Vesicles (Under revision) [IF: 25.841]
  • Tey SK#, Wong SWK#, Chan JYT, Mao XW, Ng TH, Yeung CLS, Leung Z, Fung HL, Tang AHN, Wong DKH, Mak LY, Yuen MF, Sin CF, Ng IOL, Ma SKY, Lee TKW, Cao PH, Zhong K, Gao Y, Yun JP, Yam JWP*. Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. Journal of Hepatology (Accpted) [IF: 25.083]
  • Zheng WY, Ji DL, Zhou YX, Yu L, Huang P, Zheng YL, Meng NF, Wang H, Bai X, Huang ZY, Chen WM, Yam JWP*, Xu Y*, Cui YF*. Exosomal non-coding RNAs in hepatobiliary cancer: A rising star. Molecular Cancer Therapeutics 2021, 20:1777-1788. [IF: 6.261]
  • Huang ZY Xia H, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Kang P, Su Z, Cui Y*, Yam JWP*, Xu Y*. The mechanism and clinical significance of circular RNAs in hepatocellular carcinoma. Frontiers in Oncology 2021, 11:714665. [IF: 6.244]
  • Qu X, Leung TCN, Ngai SM, Tsai SH, Thakur A, Li WK, Lee Y, Leung L, Ng TH, Yam JWP, Lan L, Lau EHL, Wong EWY, Chan JYK, Meehan K*. Proteomic analysis of circulating extracellular vesicles identifies potential biomarkers for lymph node metastasis in oral tongue squamous cell carcinoma. Cells 2021, 10(9):2179. [IF: 6.600]
  • Liu BHM, Tey SK, Mao XW, Ma APY, Yeung CLS, Wong SWK, Ng TH, Xu Y, Yao Y, Fung EYM, Tan KV, Khong PL, Ho DWH, Ng IOL, Tang AHN, Cai SH, Yun JP, Yam JWP*. TPI1-reduced extracellular vesicles mediated by Rab20 downregulation promotes aerobic glycolysis to drive hepatocarcinogenesis. Journal of Extracellular Vesicles 2021, 10:e12135. [IF: 25.841]
  • Ma APY, Yeung CLS, Tey SK, Mao XW, Wong SWK, Hg, TH, Ko FCF, Kwong EML, Tang AHN, Ng IOL, Cai SH, Yun JP, Yam JWP*. Suppression of ACADM-mediated fatty acid oxidation promotes hepatocellular carcinoma via aberrant Cav1/SREBP-1 signaling. Cancer Research 2021, 81:3679-3692. [IF: 12.701]
  • Xia H, Huang Z, Liu S, Zhoa X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y*, Yam JWP*, Cui Y*. LncRNA DiGeorge Syndrome Critical Region Gene 5: A crucial regulator in malignant tumors. Biomedicine & Pharmacotherapy 2021, 141:111889. [IF: 6.529]
  • Liu B, Zhao N, Zhou YS, Lu YX, Chen WM, Huang ZY, Wang DS, Xu Y*, Yam JWP*, Cui Y*. Circular RNA circ_ABCB10 in cancer. Clinica Chimica Acta 2021, 518:93-100.
  • Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y*, Yam JWP*, Cui Y*. Exosomal non-coding RNAs: Regulatory and therapeutic target of hepatocellular carcinoma. Frontiers in Oncology 2021, 11:653846. [IF: 6.244]
  • He R, Wang Z, Shi W, Yu L, Xia H, Huang Z, Liu S, Zhao X, Xu Y*, Yam JWP*, Cui Y*. Exosomes in hepatocellular carcinoma microenvironment and their potential clinical application value. Biomedicine & Pharmacotherapy 2021, 138:111529. [IF: 6.529]

2020

  • Mao XW#, Zhou LY#, Tey SK, Ma APY, Yeung CLS, Ng TH, Wong SWK, Liu BHM, Fung YME, Patz EF, Cao PH, Gao Y, Yam JWP*. Tumor extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumor cells. Journal of Extracellular Vesicles 2020, 10(1): e12031. [IF: 25.841]
  • Mao XW#, Tey SK#, Yeung CLS, Kwong EML, Fung YME, Chung CYS, Mak LY, Wong DKH, Yuen MF, Ho JCM, Pang H, Wong MP, Leung CON, Lee TKW, Ma V, Cho WCS, Cao PH, Xu X, Gao Y, Yam JWP*. Nidogen 1-enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1. Advanced Science 2020, 7(21): 2002157. [IF: 16.806]
  • Wang SQ, Liu J, Qin J, Zhu Y, Tin V, Yam JWP, Wong MP, Xiao ZJ*. CAMK2A supported tumor initiating cells of lung adenocarcinoma by upregulating SOX2 through EZH2 phosphorylation. Cell Death & Disease 2020, 11: 410. [IF: 8.469]

2019

  • Leung Z, Ko FCF, Tey SK, Kwong EML, Mao XW, Liu BMH, Ma APY, Fung YMF, Che CM, Wong DKH, Lai CL, Ng IOL, Yam JWP*. Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. Journal of Experimental & Clinical Cancer Research 2019, 38: 423. [IF: 11.161]
  • Mao XW, Tey SK, Ko FCF, Kwong EML, Gao Y, Ng IOL, Cheung ST, Guan XY, Yam JWP*. C-terminal truncated HBx protein activates caveolin-1/LRP6/beta-catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer Letters 2019, 444: 60-69. [IF: 8.679]

2017

  • Tey SK, Tse EYT, Mao XW, Ko ECF, AST Wong, Lo RCL, Ng IOL, Yam JWP*. Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway.  Cancer Letters 2017, 411:150-161. [IF: 8.679]

2016

  • Mao XW, Wong SYS, Tse EYT, Ko FCF, Tey SK, Yeung YS, Man K, Lo RCL, Ng IOL, Yam JWP*. Mechanisms through which hypoxia-induced caveolin-1 drives tumorigenesis and metastasis in hepatocellular carcinoma. Cancer Research 2016, 76(24): 7242-7253. [IF: 12.701]

2015

  • Tong M, Fung TM, Luk ST, Ng KY, Lee TK, Lin CH, Yam JWP, Chan KW, Ng F, Zheng BJ, Yuan YF, Xie D, Lo CM, Man K, Guan XY, Ma S*. ANXA3/JNK signaling promotes self-renewal and tumor growth, and its blockade provides a therapeutic target for hepatocellular carcinoma. Stem Cell Reports 2015, 5(1): 45-59. [IF: 7.765]

2014

  • Cai PC, Shi L, Liu VW, Liu IJ, Leung TH, Chan KK, Yam JWP, Yao KM, Ngan HY, Chan DW*. Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling. Oncotarget 2014, 5(17): 7549-7562. [IF: 5.168]
  • Liu MX, Siu MK, Liu SS, Yam JWP, Ngan HY, Chan DW*. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2014, 5(4): 944-958. [IF: 5.168]
  • Lam SS, Mak AS, Yam JWP, Cheung AN, Ngan HY, Wong AST*. Targeting estrogen-related receptor alpha inhibits epithelial to mesenchymal transition and stem cell properties of ovarian cancer cells. Molecular Therapy 2014, 22(4): 743-751. [IF: 11.454]
  • Ko FCF and Yam JWP*. Regulation of Deleted in Liver Cancer 1 tumor suppressor by protein-protein interactions and phosphorylation. International Journal of Cancer 2014, 135: 264-269. [IF: 7.396]
  • Liu XB, Cheng Q, Geng W, Ling CC, Liu Y, Ng KTP, Yam JWP, Guan XY, Lo CM, Man K*. Enhancement of cisplatin-based TACE by a hemoglobin-based oxygen carrier in an orthotopic rat HCC model. Artificial Cells, Nanomedicine, and Biotechnology 2014, 42(4): 229-236. [IF: 5.687]

2013

  • Ko FCF, Chan LK, Sze KMF, Yeung YS, Tse EYT, Lu P, Yu MH, Ng IOL, Yam JWP*. PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. Nature Communications 2013, 4: 1618. [IF: 14.919]
    • [Selected as featured article in NPG journals in cancer]
  • Shum CKY, Tsoi LLS, Lau ST, Woo JYH, Chan LK, Tse EYT, Yam JWP, Garcia-Barceló MM, Ohira M, Nakagawara A, Tam PKH and Ngan ESW*. Krüppel-Like Factor 4 (KLF4) suppresses neuroblastoma growth and determines non-tumorigenic lineage differentiation. Oncogene 2013, 32(35): 4086-4099. [IF: 9.867]

2012

  • Chen L, Liu C, Ko FCF, Xu N, Ng IOL, Yam JWP*, Zhu G*. Solution structure of the PTB domain of human Tensin2 in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode. Journal of Biological Chemistry 2012, 287(31): 26104-26114. [IF: 5.157]
  • Tse EYT, Ko FCF, Tung EKK, Chan LK, Lee TKW, Ngan ESW, Man K, Wong AST, Ng IOL, Yam JWP*. Caveolin-1 is overexpressed and associated with hepatocellular carcinoma tumorigenesis and metastasis. Journal of Pathology 2012, 226: 645-653. [IF: 7.996]

2011

  • Chan LK, Ko FCF, Sze KMF, Ng IOL, Yam JWP*. Nuclear-targeted Deleted in Liver Cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo. PLoS ONE 2011, 6(9): e25547. [IF: 3.240]
  • Chan J, Ko FCF, Ng IOL, Yam JWP*. Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS ONE 2011, 6(2): e16984. [IF: 3.240]

2010

  • Leung THY, Yam JWP, Chan LK, Ching YP, Ng IOL*. Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway. Liver Int 2010, 30(9): 1315-1323. [IF: 5.828]
  • Ko FCF, Chan LK, Tung EKK, Lowe SW, Ng IOL, Yam JWP*. Akt phosphorylation of Deleted in Liver Cancer 1 deregulates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology 2010, 139(4):1397-1407. [IF: 22.682]
    • [With editorial commentary: Wuestefeld T, Zender L. DLC1 and liver cancer: the Akt connection. Gastroenterology 2010, 139(4): 1093-1096.]
  • Tang MKS, Zhou HY, Yam JWP, Wong AST*. c-Met overexpression contributes to the acquired apoptotic resistance of non-adherent ovarian cancer cells through a cross-talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia 2010, 12(2): 128-138. [IF: 5.715]
  • Ko FCF, Yeung YS, Wong CM, Chan LK, Poon RTP, Ng IOL, Yam JWP*. Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation. Liver International 2010, 30(1): 139-148. [IF: 5.828]

Before 2010 (Selected)

  • Chan DW, Chan CY, Yam JWP, Ching YP, Ng IOL*. Prickle-1 negatively regulates wnt/beta-catenin pathway by promoting dishevelled ubiquitination/degradation in liver cancer. Gastroenterology 2006, 131:1218-1227. [IF: 22.682]
  • Yam JWP, Ko FCF, Chan CY, Yau TO, Tung EKK, Leung THY, Jin DY, Ng IOL*. Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology 2006, 44:881-890. [IF: 17.425]
  • Yam JWP, Ko FCF, Chan CY, Jin DY, Ng IOL*. Interaction of DLC1-tensin2 complex with caveolin-1 and implications in tumor suppression. Cancer Research 2006, 66:8367-8372. [IF: 12.701]
  • Wong CM#, Yam JWP#, Ching YP, Yau TO, Leung HY, Jin DY, Ng IOL*. Rho GTPase activating protein DLC1 (deleted in liver cancer 1) suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Research 2005, 65:8861-8868. [IF: 12.701]
  • Leung THY, Ching YP, Yam JWP, Wong CM, Yau TO, Jin DY, Ng IOL*. Deleted in liver cancer 2, DLC2, suppresses cell transformation via inhibition of RhoA activity. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:15207-15212. [IF: 11.205]
  • Yam JWP, Jin DY, So CW, Chan LC*. Identification and characterization of EBP, a novel EEN binding protein that inhibits ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein. Blood 2004, 103:1445-1453. [IF: 22.113]
  • Yam JWP, Chan KW, Hsiao WLW*. Transcriptional regulation of rat frizzled related protein gene promoter by CREB. Oncogene 2003, 22:3901-3910. [IF: 9.867]
  • Yam JWP, Chan KW, Hsiao WLW*. Suppression of the tumorigenicity of mutant p53-transformed rat embryo fibroblasts through expression of a newly cloned rat nonmuscle myosin heavy chain-B. Oncogene 2001, 20:58-68. [IF: 9.867]